British drugmaker GlaxoSmithKline Plc will invest US$250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.
GSK to partner with Vir for potential COVID-19 treatments, invest US$250 million
